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Modified allergens are a safer andmore efficient alternative to natural allergens for specific immunotherapy.
As the modification of an allergen can diminish its immunogenicity due to the alteration of T-cell epitopes,
in this paper we study the effects of a reversible chemical modification of Art v 1, the main allergen of
mugwort pollen, on its allergenicity and immunogenicity. Modification of Art v 1 by cis-aconitylation into
a polyanionic derivative (CAA) did not result in any significant structural alteration. However, IgE-binding
epitopes on CAA were blocked, resulting in a reduced IgE-binding and basophil activation. Both proteins
induced proliferation of CD3+CD4+ T-cells in mugwort-allergic patients, but only unmodified allergens
increased IL-4, IL-5 and IL-10 production. Rabbit and mouse anti-CAA antibodies exhibited cross-
reactivity with native allergens and blocked human IgE-binding to Art v 1. Degradation of CAA by
lysosomal fraction enzymes resulted in a similar set of peptides, harboring MHC class II-binding peptides,
as unmodified proteins. Thus, cis-aconitylation modified Art v 1 had a significantly reduced allergenicity,
whereas its immunogenicity was completely preserved. Acid-environment-responsive modification,
which releases a full repertoire of native allergen epitopes within a particular site, can be considered
a smart drug delivery system, which is able to deliver a therapeutically-effective dose in a controlled
manner, and minimizes adverse side effects.Introduction
Allergen-specic immunotherapy (ASIT) is the only desensitiz-
ing therapy for IgE-mediated allergic diseases that aims at
modifying the underlying immune mechanism. The modes of
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28mast cells and basophils; generation of regulatory T- and B-cell
responses; regulation of IgE and IgG4 levels; reduction in
numbers and activity of eosinophils and mast cells in mucosal
tissues; and bringing about a decrease in the activity of baso-
phils in circulation. Skewing of allergen-specic effector T- and
B-cell responses to a regulatory phenotype appears to be a key
event in the course of AIT.1
Current ASIT protocols are long and have a risk of anaphy-
lactic reactions when native allergens are used. Therefore,
current research is aimed at decreasing the risk of side effects
while maintaining or improving the efficacy of ASIT.2
Different strategies for increasing the safety and efficacy of
immunotherapies are under development and these strategies
target B-cells, T-cells or antigen-presenting cells (APCs). Hypo-
allergenic recombinant variants of major allergens aim at
reducing side-effects of IgE-mediated reactions, while inducing
T-cell tolerance and generation of IgG4 blocking antibodies.2,3 T-
Cell peptides of allergens that are devoid of conformational B-cell
epitopes, but long enough to bind to T-cell receptors, are exam-
ined for induction of tolerance.4 Small peptides representing
minor B-cell epitopes fused to an immunogenic carrier protein
aim at inducing blocking antibodies against conformationalThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineepitopes, but without the activation of allergen-specic T-cells.3
In addition, there are strategies that aim at dendritic cells (DCs)
and endolysosomal compartments (ELC) of APCs in particular,
i.e. the so-called LAMP-vax™ DNA vaccines, which produce the
encoded allergen sequence inside the cell as part of a fusion
protein, with a lysosomal-associated membrane protein (LAMP)3
and neoglycoallergens are delivered to dendritic cells via specic
receptors.5
Among different approaches for AIT improvement, the use of
chemically modied hypoallergenic derivatives stands out as
a clinically effective strategy that has been proven in double-
blind placebo-controlled studies for decades.6 Ideally, a modi-
ed allergen suitable for use in AIT should have its IgE binding
epitopes destroyed by modication in order to diminish (or
reduce) IgE-binding and IgE-mediated side effects, while
structural motifs necessary for T-cell recognition should be
preserved. Since many of the B- and T-cell epitopes in allergens
are virtually identical, or shared, chemical modication in an
uncontrollable manner inevitably destroys certain T-cell
epitopes and may lead to a reduced or even diminished
capacity for a modied protein to induce allergen-specic
immune responses.4–7
In this study we tested a hypothesis that an acid-sensitive
polyanionic derivative of a pollen allergen will generate a full
repertoire of native B- and T-cell epitopes during acidication in
ELC and efficiently raise cross-reactive antibodies to the native
protein (blocking antibodies), while also bypassing IgE-mediated
reactions of effector cells due tomasking of the IgE-epitopes. Our
approach included modication of the major mugwort pollen
allergen, Art v 1,7 by an acid-sensitive modication: cis-aconity-
lation of lysine 3-amino groups in the protein.8,9
We demonstrated that our approach created a hypoaller-
genic protein with a fully preserved fold and intact repertoire of
T-cell epitopes. Proling endolysosomal degradation of
proteins in APCs by mass spectrometry identied Art v 1-derived
peptides and proved the controlled delivery of a full repertoire
of T-cell epitopes in ELC.
Materials and methods
Preparation and modication of Art v 1
Art v 1 was isolated from a pollen extract of Artemisia vulgaris by
ion-exchange HPLC andmodied by cis-aconitylation according
to a previously described protocol.9 Briey, Art v 1 (1.5 mgmL1)
in 4% NaHCO3 was treated with the bolus addition of cis-aco-
nitic anhydride (Sigma-Aldrich, Steinheim, Germany) with
extensive mixing at 4 C. The nal anhydride concentration was
400 mM. Aer every bolus addition, the pH was adjusted to 9.0
with solid Na2CO3. The mixture was extensively dialyzed against
phosphate buffered saline (PBS) for 20 h at 4 C. All samples
were stored at 20 C until use. Concentrations of native and
modied proteins were determined spectrophotometrically at
280 nm using an extinction coefficient of 640 mL mg1 cm1,
calculated for Art v 1 as described previously.10
The obtained cis-aconitylated Art v 1 (CAA) had approxi-
mately 80% modied amino groups, dramatically reduced pI
and low stability in acidic conditions.9This journal is © The Royal Society of Chemistry 2016CD spectrometry and uorimetry measurements
Far UV CD spectra were recorded on a JASCO J-815 spec-
tropolarimeter (JASCO, Japan) with Art v 1 and CAA at
a concentration of 1 mg mL1 in PBS. Each spectrum was
acquired four times, and the results were averaged. Results were
expressed as a residue-average molar ellipticity as follows: [q] ¼
q/(10  n  C  d), where q is the measured ellipticity, n is the
number of Art v 1 amino acid residues, C is the molar concen-
tration of the Art v 1 sample, and d is the path length of the cell.
Spectra were analyzed by CONTIN soware to determine the
percentage of b-sheet, a-helical and random coil structures
using the CDPro soware package (http://lamar.colostate.edu/
sreeram/CDPro/main.html). For the calculations, a reference
protein base set, SP37, was used.
Fluorescence measurements were performed using a Horiba
Scientic Fluoromax-4 Spectrouorometer (Horiba, Kyoto,
Japan). For intrinsic tryptophan uorescence measurements Art
v 1 samples were diluted in 10 mM potassium phosphate buffer
(pH 6.5) to give a nal concentration of 0.5 mM and emission
spectra were recorded with an excitation wavelength of 280 nm
(5 nm slit width). For hydrophobic ligand binding experiments,
the uorescence spectra of the Art v 1 solutions (16 mM in 10
mM potassium phosphate buffer pH 6.5) saturated using 80 mM
of 8-anilino-1-naphthalenesulfonic acid (ANS, Sigma-Aldrich) in
10 mM sodium phosphate buffer pH 8 were recorded with an
excitation wavelength of 350 nm.Immunization of rabbits and determination of specic IgG
antibody levels by ELISA
The animals were treated according to Directive 2010/63/EU of
the European Parliament and the Council of 22 September 2010
on the protection of animals used for scientic purposes. All
animal procedures were approved by the Ethical Committee for
the Use of Laboratory Animals of the Institute for Biological
Research “Siniˇsa Stankovic´”, University of Belgrade (No. 2-20/
10).
The antibodies against Art v 1, CAA and irrelevant proteins
(kiwi fruit protein extract) were raised in rabbits according to
Harboe & Ingild11 and as previously described for acetylated Art
v 1.12 All experiments were approved by the Ethics Committee
for Animal Experimentation at Belgrade University. Two rabbits
were immunized subcutaneously with each of the two proteins
and the serum obtained by pooling serum specimens of two
rabbits was used for experiments. Before the rst immuniza-
tion, serum samples were taken as the reference point, and then
every 2 weeks aer 51 days from the start of immunization. For
direct ELISA, Art v 1 and CAA were coupled to the microtiter
plates (Nunc, MaxiSorp, Roskilde, Denmark, 5 mg mL1) and the
total IgG levels were determined by ELISA using anti-rabbit IgG
(whole molecule) alkaline phosphatase (AP) labeled antibodies
(Sigma-Aldrich) and 4-nitrophenyl phosphate (4-NPP, Sigma-
Aldrich) as the substrate. Rabbit serum was diluted 1 : 100 in
a diluting buffer consisting of 0.5% BSA in Tris-buffered saline
(pH 7.4) containing 0.05% Tween-20 (TTBS), and then double
fold serial dilutions were performed in the same buffer. In total,
12 double fold serial dilutions were done. A control series wasRSC Adv., 2016, 6, 88216–88228 | 88217
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View Article Onlinedone on the same plates with the rabbit antiserum raised
against kiwi fruit extract proteins. Absorbance was measured at
405 nm aer adjusting the background with the negative
control. Samples were measured and mean values of the two
replicas were presented.
Human sera
Sera from 13 patients with a positive skin prick test to mugwort
pollen, a documented clinical history of a mugwort pollen
allergy and with no previous immunotherapy to mugwort
pollen, were used for ELISA inhibition and blocking experi-
ments. Fresh heparinized blood was used for basophil activa-
tion and lymphocyte proliferation assay. Informed consent was
obtained before the start of the study from all patients for their
sera to be used for research purposes. The study was approved
by the Ethical Committee of the University Children's Hospital,
Belgrade, Serbia (No. 017/6-990/66), and was performed in
compliance with the Declaration of Helsinki.
Inhibition of human IgE and rabbit IgG binding in ELISA
assay by Art v 1 and CAA
The microtiter plates were coated with 50 mL of Art v 1 (5 mg
mL1 in 0.1 M carbonate buffer, pH 9.6) overnight and washed
with TTBS. Aer blocking with 100 mL of 1% BSA in TTBS, 50 mL
of an individual's human sera, previously incubated with 50 mL
of serially 10-fold diluted Art v 1 or CAA in tubes for 30 min at 4
C, were added to the plates. Human serum pool was used at
a dilution sufficient to achieve 80% of IgE binding to the
coupled antigen, as determined in a separate ELISA. For inhi-
bition, serial dilutions of unmodied and modied Art v 1 were
prepared in a buffer consisting of TTBS–0.5% BSA. The
remaining unbound IgE that binds to the Art v 1 coupled plate
was detected using anti-human IgE antibodies labeled with AP
(Sigma-Aldrich) and 4-NPP as the substrate. Absorbance was
measured at 405 nm aer adjusting the background with the
negative control. The percentage of inhibition was calculated as
follows: % inhibition ¼ (OD of the test sample  (OD of the
inhibited sample/OD of the test sample sample)) 100. The test
sample (positive control) was 50 mL of the two-fold diluted
human serum incubated with 50 mL of diluting buffer. All steps
were performed at room temperature. ELISA inhibition with
rabbit sera (5000 times diluted) was done in the same way and
detection was done with anti-rabbit IgG antibodies labeled with
AP.
Competition ELISA for assessment of blocking human IgE
antibody
The microtiter plates were coated with Art v 1 (5 mg mL1). Aer
blocking with 1% BSA in TTBS, the plates were pre-incubated
(1 : 1) with serial dilutions (4 to 1024) of rabbit antibodies
generated to Art v 1 and CAA during 30 min. Two rabbits were
immunized with each protein and the serum obtained by
pooling serum specimens of two rabbits was used for experi-
ments. Aer that, pooled sera of mugwort pollen allergic
patients, which were 1.5 times diluted, were incubated for 90
min and the remaining unblocked IgE that binds to the Art v 188218 | RSC Adv., 2016, 6, 88216–88228coupled to the plate was detected using antihuman IgE anti-
bodies labeled with AP.Lymphocyte proliferation assay in human peripheral blood
mononuclear cell (PBMC) cultures
PBMCs were obtained from the heparinized venous blood of 10
mugwort-allergic patients and cultured exactly according to
Perovic et al.12 Stimulation of the PBMCs with allergens and
a lymphocyte proliferation assay were done as described.12 The
PBMCs were stimulated for 7 days with Art v 1, CAA (10 mgmL1)
or unstimulated with medium alone in duplicates. Tetanus
toxoid (TT) (5 mg mL1, Torlak, Serbia) was used as a positive
control. As a measure of stimulation, the number of prolifer-
ating CD3+CD4+ cells (CD3+CD4+ cells among gated blasts) is
expressed as the number of proliferating cells per 100 000
lymphocytes (resting and proliferating lymphocytes). Superna-
tants, collected for determination of cytokines (IL-2, IL-4, IL-5,
IL-10, TNF-a and IFN-g), were analyzed using the Th1/Th2
cytometric bead array-kit (BD Biosciences) according to the
manufacturer's instruction.Basophil activation assay
The expression of CD203c was performed as previously
described.12 Briey, heparinized blood samples were taken from
three mugwort-allergic patients. Blood aliquots (100 mL) were
incubated with dilutions of Art v 1 and CAA (106, 105, 104,
103, 102 and 0.1 mg mL1), anti-IgE antibody was taken as
a positive control (1 mgmL1), or PBS as a negative control for 15
min (37 C). Aer incubation, cells were washed in PBS and then
incubated with 10 mL of phycoerythrin (PE)-labelled CD203c
monoclonal antibody (Beckman Coulter, USA) and uorescein-
isothiocyanate (FITC)-labelled CD63 monoclonal antibody
(Beckman Coulter) for 15 min at room temperature. Thereaer,
samples were subjected to erythrocyte lysis with 2 mL of FACS™
lysing solution (BD Biosciences, USA). Cells were then washed,
resuspended in PBS, and analysed by ow cytometry using
a FACSCalibur (BD Biosciences). The magnitude of basophil
activation was calculated as the percentage of CD63+ events
among the gated basophils (CD63+CD203c+).Immunization of mice and determination of specic antibody
responses in ELISA assay
The age-matched (eight-week-old) male C57BL/6 mice were
used in the experiments. The animals were obtained from our
own animal facility at the Institute for Biological Research
“Sinisa Stankovic” (Belgrade, Serbia). Mice (seven mice per
group) were immunized (i.p.) for 6 weeks with 100 mg of Art v 1
or CAA adsorbed onto 200 mL of alum (0.4% Al(OH)3) per
immunization. Control groups were immunized with 200 mL of
alum and PBS instead of allergens. Alum was prepared
according to the method reported by Gupta.13 Immunizations
and bleedings were done at two week intervals (day 0, 14 and
28). Final bleeding was done on day 42. Sera were stored at 80
C until analysis. IgE, total IgG, IgG1, IgG2a and IgG2b
responses were measured by ELISA.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineELISA plates were coated with 100 mL per well of allergens (5
mg mL1 in PBS) overnight. Aer washing with TBS–0.05%
Tween plates were blocked for 90 min with 1% BSA in TTBS and
mice sera (100 mL per well) diluted in TTBS–1% BSA were added
(IgE, 1 : 3; IgG2a, 1 : 10; IgG2b, 1 : 10, IgG1, 1 : 300; and total
IgG, 1 : 300). In parallel, positive anti-Art v 1 serum pool was
serially diluted in order to estimate specic antibody arbitrary
units, as previously described.14 The plates were incubated with
sera in duplicate overnight at 4 C and washed three times in
TTBS. Bound mouse antibodies were detected aer 3 h of
incubation with 100 mL of biotin-labeled monoclonal anti-
mouse IgE, anti IgG1, IgG2a and IgG2b antibodies (BioL-
egend, San Diego, CA) diluted in TTBS–1% BSA (1 mg mL1) and
alkaline phosphatase-labeled goat anti-mouse IgG diluted
1 : 15 000 (Sigma-Aldrich). Aer washing with TTBS three times,
avidin-AP (Sigma-Aldrich) or AP-labeled anti-goat IgG (Sigma-
Aldrich) was added and maintained for 2.5 h. The plates were
again washed three times with TTBS and 4-NPP was added as
the substrate.Endolysosomal degradation assay and peptide analysis
following mass spectrometry
A microsomal fraction was isolated from BALB/c DCs by
differential centrifugation and characterized as described
previously.14 Endolysosomal degradation assays were per-
formed with 0.25 mg mL1 of Art v 1 and CAA and 0.4 mg mL1
of isolated microsomal proteins in a nal volume of 20 mL,
containing 100 mM citrate buffer, pH 4.8, and 2 mM dithio-
threitol (DTT). Reactions were conducted for 15 min, 3, 12, 24,
and 48 h at 37 C and stopped by boiling for 5 min at 95 C
followed by freezing at 20 C. Digests were analyzed by SDS-
PAGE according to the method reported by Laemmli15 on
a 12% polyacrylamide gel with a standard protein mixture
(Sigma-Aldrich) for a molecular weight reference. Gels were
stained with Coomassie brilliant blue R-250 (Sigma-Aldrich).
The bands obtained were quantitatively evaluated by
densitometry.
For mass spectrometry analysis, the samples were diluted
ten times with a 1% solution of formic acid. Peptides were
analyzed on an EASY nLC II system coupled with a LTQ Orbitrap
XL (Thermo scientic Inc., MA, USA) previously calibrated with
the ProteoMass™ LTQ/FT-Hybrid ESI Positive Mode Cal Mix
(MSCAL5 SUPELCO, Sigma Aldrich) calibration set. In total, 240
ng of proteins were injected onto the EASY-Spray PepMap C18
Column (150  0.075 mm, 3 mm particle size). Solvent A was
a 0.1% formic acid aqueous solution and solvent B was 0.1%
formic acid in acetonitrile. A 50 min gradient from 5–70% of
solvent B was applied using a 300 nL min1 ow rate. The CID
normalized collision energy value was 35.0%. Parameters for
Nanoelectro Spray Ionization (NSI) were as follows: spray
voltage +3.91 kV, capillary voltage 6 V, capillary temp 275 C,
tube lens 100V. Spectra were recorded in positive mode in the
range of m/z 500–3000. The ve most intense monoisotopic
peaks in the spectra were fragmented using collision-induced
dissociation and measured in the linear ion trap.This journal is © The Royal Society of Chemistry 2016Predictions of the peptide sequences were done using the
exact masses obtained using MS, exact masses of the native
isoforms (Uniprot Q84ZX5) and the peptide calculator tool
(http://pepcalc.com/). For the theoretical mass calculations in
the peptide calculator, the amino acid sequence for Art v 1
(Uniprot Q84ZX5) was used. To take into account post-
translational modications, mass additions of 16 Da for the
hydroxylation of proline, 2, 4, 6 or 8 Da for partial reduction, as
well as 162 Da for galactose and 132 Da for arabinose were used.
The digestion resistant peptides of Art v 1 were modeled in
the Modeller soware (http://salilab.org/modeller/) based on
the NMR solved structure of Art v 1, pdb 2KPY.16Statistics
For all experiments, differences were compared statistically
using the Wilcoxon matched pairs test and the Statistica 9.0
program, except for the analysis of the IC50 values in the ELISA
inhibition assay of IgE binding by Art v 1 and CAA, in which
a paired sample t-test (P < 0.05) was used.Results
Extensive cis-aconitylation of Art v 1 does not change protein
folding
Following the modication of lysine residues, approximately
80% of the positively charged amino groups in the protein were
replaced by double-negative groups of cis-aconitic acid. A
signicant repulsion between the highly charged surface resi-
dues, particularly in the lysine-rich defensin globe of Art v 1,17
may result in a partial unfolding of the protein. Thereby, the Art
v 1 and CAA secondary and tertiary structures by circular
dichroism, Trp emission uorescence and ANS binding were
probed.
CD spectra were obtained for both proteins with a negative
peak at 203 nm (Fig. 1A), which is in accordance to previous
ndings.17,18 We calculated the % of a-helix, b-sheet, b-turn and
random coil (Fig. 1B). The secondary structure content of Art v 1
was virtually unaffected by the modication.
In order to get insight into the tertiary structure changes
induced by cis-aconitylation, intrinsic tryptophan uorescence
emission spectra were examined (Fig. 1C). When excited at 280
nm, native Art v 1 exhibited a uorescence emission maximum
(lmax) at 352 nm, originating from the only solvent exposed
tryptophan residue (Trp 29) located in the defensine domain. A
decrease in intensity was observed due to the quenching of the
tryptophan uorescence by the charged cis-aconityl groups.
However, negligible red shiing of the lmax to 353 nm and the
uorescence spectra retaining the overall shape in CAA indi-
cates that cis-aconitylation only slightly disrupted the Art v 1
tertiary structure.
Upon non-covalent binding of the polarity-sensitive hydro-
phobic uorescent probe ANS to hydrophobic patches on the
protein surfaces, the uorescence intensity increases and the
wavelength of emission maximum demonstrates a blue shi.
The decreased ANS binding to CAA with a red shi (from 471 to
475 nm) reects a higher degree of accessibility for waterRSC Adv., 2016, 6, 88216–88228 | 88219
Fig. 1 Secondary and tertiary structural properties of native and cis-aconitylated Art v 1. (A) Far UV CD spectra of Art v 1 and CAA (1 mg mL1 in
PBS pH 7.2), (B) calculated content of the secondary structure fractions, (C) intrinsic tryptophan fluorescence emission spectra of Art v 1 and CAA
(0.5 mM in 10 mM potassium phosphate buffer, pH 6.5) when excited at 280 nm (D) binding of polarity-sensitive hydrophobic fluorescent probe
ANS (80 mM) to hydrophobic patches on protein surfaces of native and cis-aconitylated Art v 1 (16 mM in 10 mM potassium phosphate buffer
pH 6.5).
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View Article Onlinemolecules to the ANS binding region within CAA, indicating
that modied Art v 1 has slightly less hydrophobic surfaces
(Fig. 1D). These results suggest that cis-aconitylation did not
substantially disturb the secondary and tertiary structure of Art
v 1, in spite of the fact that Art v 1 was extensively modied by
acylation.cis-Aconitylation masks the surface of Art v 1 and reduces
specic IgG and IgE binding
To investigate whether the modication of Art v 1 altered
protein epitopes, we rst raised antibodies against Art v 1 in
rabbits and analyzed the inhibitory potential of Art v 1 and CAA
for rabbit anti-Art v 1 IgG binding to an Art v 1 coupled plate
(Fig. 2A). The IC50 values for Art v 1 and CAA were 0.09 and 15.85
mg mL1, respectively, and with inhibitor concentration of 100
mg mL1, an inhibition of 100% was achieved for Art v 1,
whereas an inhibition of only 60% was achieved for CAA. This
implies that the introduced acyl groups masked the Art v 1
epitopes so that they are weakly recognized by Art v 1 specic
antibodies.88220 | RSC Adv., 2016, 6, 88216–88228IC50 values obtained for the inhibition of human IgE binding
to Art v 1 (Fig. 2B) with 13 individual sera from mugwort pollen
allergic patients were consistent with the aforementioned
result. The IC50 values for Art v 1 and CAA were in the range
from 0.001 to 0.656 mg mL1 (mean ¼ 0.071), and 0.318 to
22.656 mg mL1, respectively. For all tested sera, the IC50 values
increased from 10 to 575-times (mean ¼ 188, n ¼ 13) for CAA
compared to Art v 1. This result indicates that the IgE binding
epitopes in CAA were signicantly altered and cis-aconitylation
signicantly (p < 0.05) reduced the Art v 1 allergenic potency in
the tested group of mugwort-allergic patients.
A signicant alteration in the IgE-binding epitopes of CAA
also resulted in its reduced ability to degranulate effector cells
in the three mugwort pollen-allergic patients. In comparison to
Art v 1, a higher concentration of CAA was needed to induce
upregulation of CD63 on CD203c+ cells of allergic donors
(Fig. 2C). In one of the tested allergic donors (Fig. 2C, #3), CAA
did not induce a signicant degranulation of basophils, even at
the highest concentration that was tested. These results indi-
cate that IgG and IgE epitopes of Art v 1 were signicantlyThis journal is © The Royal Society of Chemistry 2016
Fig. 2 IgG and IgE binding properties of native andmodified Art v 1. (A) ELISA inhibition of IgG binding to the Art v 1 coupled to the plate by rabbit
sera immunized by Art v 1 or CAA. Rabbit sera, previously incubated with serially 10-fold diluted Art v 1 or CAA, were added to the plates and the
remaining unbound IgG that binds to the Art v 1 coupled plate was detected. (B) Analysis of IC50 (mg mL1) values obtained using an ELISA
inhibition assay of IgE binding from 13 individual mugwort pollen allergic patients' sera by Art v 1 and CAA. Individual human sera, previously
incubated with serially 10-fold diluted Art v 1 or CAA, were added to the plates and the remaining unbound IgE that binds to the Art v 1 coupled
plate was detected. Increase in IC50 value corresponds to a decrease in IgE-binding capacity (P < 0.05, paired sample t-test). (C) Basophile
activation test in three representative mugwort pollen-allergic patients measured with six different concentrations of Art v 1 and CAA. Anti-IgE
antibody was used as a positive control.
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View Article Onlinemodied in CAA which results in a reduced ability to degra-
nulate effector cells.Fig. 3 Proliferation of CD3+CD4+ cells in response to Art v 1, CAA and
tetanus toxoid (TT) in 10 mugwort pollen allergic donors' PBMC. The
PBMCs were stimulated during 7 days with Art v 1, CAA (10 mg mL1),
tetanus toxoid (5 mg mL1) as a positive control, or were unstimulated
(with medium alone). Statistical significance: *p < 0.05.CD4+ T-cells proliferation and cytokine response to Art v 1 and
CAA in PBMC cultures of mugwort-allergic patients
In order to characterize T-cell responses to modied Art v 1,
CD3+CD4+ cell proliferation and cytokine response to Art v 1
and CAA in PBMC, cultures of 10mugwort-allergic patients were
monitored (Fig. 3). T-Cell proliferation to Art v 1 (p < 0.05) and
CAA (p < 0.05) was statistically signicant when compared to
unstimulated cells (Fig. 3A). The proliferating response to CAA
did not differ from the response to Art v 1, suggesting that T-cell
epitopes were preserved.
In response to Art v 1 stimulation, increased amounts of IL-4
(p < 0.05), IL-5 (p < 0.05) and IL-10 (p < 0.01) were detected in
donors (Fig. 4B–D). However, there were no statisticallyThis journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 88216–88228 | 88221
Fig. 4 Th1/Th2 type of cytokines induced in PBMC by stimulation with Art v 1, CAA and TT. The PBMCswere stimulated during 7 days with Art v 1,
CAA (10 mgmL1), tetanus toxoid (5mgmL1) as a positive control, or were unstimulated (withmedium alone). In collected supernatants, levels of
secreted cytokines were determined: (A) IL-2, (B) IL-4, (C) IL-5, (D) IL-10, (E) IFN-g and (F) TNF-a. Statistical significance: **p < 0.005 and *p <
0.05.
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View Article Onlinesignicant increases in IL-4, IL-5 and IL-10 production in the
cytokine response to CAA, as compared to the unstimulated
cultures. In addition, PBMC stimulated with CAA induced less
IL-4 (p < 0.05), IL-5 (p < 0.05) and IL-10 (p < 0.01) than native Art v
1. Based on the cytokine proles, it appears that cis-aconitylated
Art v 1 stimulated a Th2-like cell response in PBMC to a much
lower extent than Art v 1, although the number of CD3+CD4+
proliferating cells did not differ signicantly.CAA raises anti-Art v 1 antibodies in rabbits
For the evaluation of CAA capacity to induce an IgG response,
rabbit sera obtained by immunization with native or modied88222 | RSC Adv., 2016, 6, 88216–88228Art v 1 were tested in direct ELISA experiments. In direct ELISA
anti-Art v 1 and anti-CAA sera recognized Art v 1 at almost the
same extent (Fig. 5B). In contrast, when CAA was coupled to the
plate, Art v 1-specic antibodies did not recognize epitopes on
themodied protein, which is in accordance with data obtained
in ELISA inhibition. However, the rabbit antibodies generated
to the modied protein, recognized both the native and the
modied protein (Fig. 5B). These results support our hypothesis
that acylated Art v 1 can induce production of Art v 1 specic IgG
antibodies of high specicity in vivo.
To investigate the potential to block allergen-specic IgE,
rabbit IgG antibodies generated to Art v 1 and CAA were testedThis journal is © The Royal Society of Chemistry 2016
Fig. 5 Immunogenicity of Art v 1 and CAA in rabbits and blocking
potential of rabbit antibodies raised to Art v 1 and CAA. Direct ELISA for
detection of IgG binding from the sera of rabbits immunized by Art v 1
(circles) and CAA (squares) to plate coupled with (A) CAA and (B) Art v 1.
Control series were done on the same plates with the rabbit antiserum
raised against irrelevant kiwi fruit extract proteins (triangles). 12 double
fold serial dilutions of rabbit sera were done. (C) Blocking capacity of
rabbit antibodies, generated to Art v 1, CAA and irrelevant extract, for
IgE reactivity to Art v 1 in serum pools of mugwort pollen allergic
patients. Pooled sera of mugwort pollen allergic patients (1.5 times
diluted) were incubated with serial dilutions (4 to 1024) of rabbit
antibodies, raised to Art v 1, CAA and kiwi extract as a control, and the
remaining unblocked human IgE that binds to the Art v 1 coupled to
the plate was detected.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinein an experiment of blocking of the binding of IgE from the
serum pool of mugwort pollen allergic patients to the Art v 1-
coupled microtiter plate (Fig. 5C). At low sera dilutions (4 and
16), rabbits' anti-CAA and anti-Art v 1 completely blocked
human IgE binding to Art v 1. At higher rabbit sera dilutions,
anti-CAA exerted a higher blocking capacity (p < 0.05), implying
that immunization with CAA resulted in the production of more
efficient blocking antibodies of a slightly higher titer.
Immune response to Art v 1 and CAA in C57BL/6 mice is
similar in quantity and quantity of anti-Art v 1 generated
antibody subtypes
In order to test the immune response to Art v 1 and its cis-aco-
nityl derivative in a mouse model, C57BL/6 mice were immu-
nized and Art v 1-specic IgE, total IgG, as well as IgG subtypes
IgG1, IgG2a and IgG2b responses were analyzed by ELISA.
Our results demonstrate that both Art v 1 and CAA immu-
nization only slightly increased IgE production (Fig. 6A and B).
Both Art v 1 forms induced a signicant (p < 0.05) increase in
total IgG, and there was a tendency of CAA to induce a higher
IgG response (Fig. 6C and D). These results demonstrate that
the modied Art v 1 maintains the ability to suitably stimulate
the immune system to produce specic IgG antibodies directed
towards the native Art v 1. Moreover, immunization of mice did
not generate signicant amount of IgE to CAA.
To get better insight into the differences in IgG responses
between Art v 1 and CAA, we have determined the IgG subtypes.
Mice immunized with both Art v 1 and CAA demonstrated
signicantly increased production of IgG1, compared to alum
alone (p < 0.005), Fig. 7A and B. However, generation of IgG2a
and IgG2b antibodies was not signicantly increased in either
Art v 1 or CAA-immunized mice (Fig. 7C–F).
Assessing Art v 1 and CAA immunogenicity with a DC-derived
endolysosomal degradome
We applied an endolysosomal in vitro degradation assay with
isolated total endolysosomal fractions from murine DCs14 to
compare the susceptibility of CAA and Art v 1 to endolysosomal
proteases. We have used HRP as an internal reference to esti-
mate proteolytic activity of the obtained microsomal prepara-
tion. The half-life of HRP (1.5 h) was found to be similar to the
one that was obtained by Egger et al.19 using the same procedure
for endolysosomal fraction preparation. Art v 1 appeared to be
very resistant to the endolysosomal proteases of DC, with a half-
life of about 26 h, in comparison to Bet v 1.401 (3.8 h) obtained
by Egger et al.19 in a similar degradation system. CAA, with an
average half-life of 40 h, was slightly more resistant to degra-
dation than Art v 1 (Fig. 8A and C).
We analyzed the most dominant high molecular mass
peptides by high-resolution mass spectrometry, in order to
compare degradation patterns of the native and modied Art v
1. Due to the extremely high diversity of hydrolyzed
hydroxyproline-rich domain (Table S1 and Fig. S1 and S2†), it is
difficult to map its degradation, but we were able to monitor the
degradation of the less variable defensin domain (Fig. 8B, Table
S2 and Fig. S3–S12†). Aer 15 min of endolysosomal processing,RSC Adv., 2016, 6, 88216–88228 | 88223
Fig. 6 IgG and IgE responses in mice immunized with Art v 1, CAA and alum alone. Rabbit sera, obtained by immunization with Art v 1, CAA and
alum alone, were tested in direct ELISA experiments. IgE levels were determined when plates were coupled with Art v 1 (A) or CAA (B), and IgG
response was determined when plates were coupled with Art v 1 (C) or CAA (D). In parallel, positive anti-Art v 1 serum pool was serially diluted in
order to estimate specific antibody arbitrary units. Statistical significance: **p < 0.005 and *p < 0.05.
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View Article Onlinethe most dominant peptide, with the highest relative intensity,
was peptide #15 (5909 Da), originating from and containing the
whole defensin domain, which is invariable in all Art v 1 iso-
forms (Fig. 8B). Its generation in the rst minutes of processing
suggests that the most proteolysis prone site on Art v 1 is a small
linker between defensin and the hydroxyproline-rich domain.
Later on, this peptide becomes more and more shortened, and
aer 48 h the most dominant peptide is 19 (5566 Da), which
consists of the whole defensin domain shortened by the N-
terminal Lys and C-terminal Cys, suggesting that the defensin
domain is highly resistant to proteolytic degradation. Almost
the same pattern was observed in Art v 1 and CAA, implying that
acid-sensitive modication enabled undisturbed degradation
by endolysosomal proteases. In fact, modications of Lys resi-
dues impede recognition and action of enzymes, such as
cathepsin S,19 favoring the cleavage of peptide bonds on the
carboxyl side of the Lys residues.
The other peptides originating from the defensin domain, as
shown in Fig. 8B and summarized in Table S3,† demonstrate
that endolysosomal degradation of CAA and Art v 1 results in
very similar peptide patterns, suggesting that CAA is capable of
providing the same, or a very similar repertoire of MHC class II
peptides for binding to T-cell receptors.88224 | RSC Adv., 2016, 6, 88216–88228Discussion
In this study, we report the reversible modication of an
allergen with the aim of reducing allergenicity while completely
preserving allergen recognition by T-cells. The puried allergen,
Art v 1, was modied with cis-aconitic anhydride, which reacts
with free amino groups (lysine and free N-terminus) on proteins
similar to a reaction with other acid anhydrides,20 resulting in
a monomeric modied protein that is able to bypass mucosal
barriers if applied locally.21 However, cis-aconitylation is
a reversible modication due to acyl group hydrolysis under
acidic conditions,8,9,22 and hence during processing in endoly-
sosomal compartments, the allergen completely recovers its
native structure.
It is known that IgE antibodies to Art v 1 are mostly directed
against the defensin domain.17,23 By mapping the interactions
between Art v 1 and human IgE antibodies, it was shown that
IgE interaction sites on Art v 1 are predominantly positively
charged.12,16 cis-Aconitylation converts positively charged amino
groups into double negative groups, hence resulting in
a marked reduction in rabbit IgG and human IgE binding in
applied ELISAs and ex vivo basophil degranulation assay.
Although the modication did not result in a signicant changeThis journal is © The Royal Society of Chemistry 2016
Fig. 7 IgG subtyping in mice immunized with Art v 1, CAA and alum alone. Rabbit sera, obtained by immunization with Art v 1, CAA and alum
alone, were tested in direct ELISA experiments. Plates are coupled with Art v 1 (A, C and E) for determination of IgG1, IgG2a and IgG2b levels,
respectively, or with CAA (B, D and F) for determination of IgG1, IgG2a and IgG2b response, respectively. In parallel, positive anti-Art v 1 serum
pool was serially diluted in order to estimate specific antibody arbitrary units. Statistical significance: ***p < 0.001, **p < 0.005, *p < 0.05.
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View Article Onlinein protein folding, extensive acylation was efficient in reducing
human IgE binding 10 to 575-times in ELISA inhibition with
individual human sera.
Further, retaining immunogenicity in animals and the
capacity to induce T-cells proliferation of the cis-aconitylated Art
v 1 derivative was demonstrated. Both Art v 1 and CAA induced
antigen-specic proliferation of PBMCs from mugwort allergic
donors. However, in contrast to Art v 1, which induced typical
Th2 type cytokines, IL-4, IL-5 and IL-10, T-cell response to the
CAA resulted in low cytokine production in PBMCs cultures.
Nonprofessional APCs from PBMCs uptake antigens via IgE (e.g.This journal is © The Royal Society of Chemistry 2016B-cells) and present them to T-cells.24 As CAA has a far lower
affinity for IgE than Art v 1, it seems that inefficient uptake and
presentation of CAA via B-cells provided a lower secretion of Th2
type cytokines.25,26
The rabbit IgG antibodies, induced by immunization with
CAA, were capable of recognizing the native Art v 1 and effec-
tively block human IgE binding to Art v 1. In mice, immuniza-
tion with CAA led to a similar pattern of humoral immune
response. An efficient immunogenicity of CAA may also be due
to the more efficient uptake via scavenger receptors (SRs). SRs
are expressed on macrophages, B-cells and DCs and recognizeRSC Adv., 2016, 6, 88216–88228 | 88225
Fig. 8 Endolysosomal in vitro degradation of Art v 1 and CAA during 15 min, 3, 12, 24 and 48 h, using isolated total endolysosomal fractions from
murine DCs. (A) Kinetics of endolysosomal degradation of Art v 1 and CAAmonitored by SDS PAGE (under reducing conditions), (B) time course of
liberation of peptides during endolysosomal degradation of Art v 1 and CAA, (C) remained intact protein (%) during endolysosomal proteolysis of
Art v 1 and CAA, calculated from densitometrically quantified protein bands, (D) 3D model of Art v 1 (red), based on NMR structure of Art v 1 (PDB
entry 2KPY), overlapped with peptide number 15 identified after 15 min, 3 h and 12 h of endolysosomal degradation of Art v 1 and CAA (blue).
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View Article Onlinediverse polyanionic ligands,27 including many proteins modi-
ed by acylation to enhance their negative charge.8,28
It is known that DCs and macrophages are more efficient
APCs than B-cells and monocytes of PBMCs, and those APCs
from PBMCs are not the actual target APCs for allergen-specic
immunotherapy.29 Thereby, in-depth analysis of endolysosomal
processing of CAA was undertaken in an in vitro degradome
system obtained from dendritic cells. Aer endolysosomal in
vitro degradation, almost the same peptide pattern was
observed in Art v 1 and CAA, implying that the applied reversible
modication enabled a similar degradation by endolysosomal88226 | RSC Adv., 2016, 6, 88216–88228proteases. It is known that antigens displaying a weak capacity
for T-cell priming in vivo were highly susceptible to endolyso-
somal proteases in vitro.19 Art v 1 harbors only a single immu-
nodominant T-cell epitope (25–36) in the defensin domain and
is recognized by 85% of the Art v 1-reactive mugwort pollen
allergic patients.30 Epitope mapping of T-cells demonstrated
that 14 of 17 patients recognized an Art v 1 epitope in the region
22–36, while ve patients recognized an epitope contained in
the 43–54 region.31 In our study of the 37 peptides found, region
22–36 was completely retained in 34 identied peptides and
region 43–54 in 18 peptides.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineDisulde bonds stabilizing typical a/b folding of the Art v 1
defensin domain32 are arranged with one (C6–C53) external,
and three internal disuldes which criss-crossed each other
(C17–C37, C22–C47, and C26–C49), resulting in a central
defensin region that was more tightly packed and less acces-
sible to proteolytic enzymes. This can explain why we found that
most of the degradation resistant peptides are contained in this
region and preferably present the immunodominant peptide.
Moreover, it was demonstrated that IgE-binding to the Art v 1
single cysteine mutants, C6S and C53S, was almost completely
retained,16 while complete loss or only marginal IgE reactivity
was observed upon disruption of disulde bonds C22–C47,
C26–C49, or C17–C37, supporting the existence of a tightly
packed internal core important for epitope formation, and
being hardly accessible to enzyme attack. Under the applied
conditions (presence of 2 mMDTT) there was limited reduction,
and it appeared that the C6–C53 disulde was most prone to
reduction, which allowed protease to attack up to the internal
core, but not the core itself. In the endolysosomal system of
APCs, where some of the reductive processes occur,33 the same
destiny of the defensin domain could be expected.
In this study, the strategy was focused on the temporary
masking of defensin domain epitopes to abrogate IgE binding
and also the preservation of the structural motifs necessary for
T-cell recognition. Our acid environment-responsive modica-
tion aims to deliver epitopes of native Art v 1, by releasing them
within a particular site. Therefore this approach can be
considered as a “smart” drug delivery system that is able to
deliver a therapeutically effective dose in a controlled manner,
while minimizing adverse side effects.
There are several advantages to this approach that greatly
improve the safety and efficiency of AIT. Firstly, modication
results in reduced specic IgE binding, providing reduced
allergenic activity and improved safety of allergen vaccine.
Secondly, the reversibility of the modication enables the
conversion of a modied protein to a native, immunologically
fully active, allergen, providing high efficiency and safety. Third,
in spite of the reversibility of the modication, the obtained
allergen derivative is stable in neutral conditions and it is
transformed to the native allergen only in the lysosomal
compartment, under the control of intracellular acidication in
APCs, where it is degraded.
Preservation of the allergen monomeric molecular size will
enable its application in local immunotherapy, in addition to
the traditional, subcutaneous application route. Applications of
organic acid anhydrides, which are highly reactive and readily
transform into organic acids with very low toxicity, further
ensure safe preparation.
Conclusions
Herein, an acid-sensitive modication of an allergen, which
enables the selective blockage of IgE-binding epitopes and
reduction of the protein allergenicity without affecting the T-cell
epitopes, protein folding, immunogenicity and capacity to
mount an immune response to the level of unmodied protein,
is described. The approach described in this study efficientlyThis journal is © The Royal Society of Chemistry 2016targeted subcellular compartment directed conversion of an
acid-sensitive scaffold for a modied protein, enabling the
controlled release of a native allergen, while bypassing IgE
antibodies and effector mechanism in the allergy. This
approach opens up new opportunities in the creation of safe
and effective allergovaccines where immunogenicity is fully
retained, in contrast to irreversible modications. Moreover,
this approach can be applied to quickly and efficiently improve
the safety of any AIT strategy, as it can be applied to puried
proteins, native allergenic extracts or allergens produced by
recombinant technology.
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